Alopexx, Inc., a clinical-stage biotechnology company focused on developing novel, broad-spectrum immune-mediated therapeutics for the prevention and treatment of bacterial, fungal, and parasitic infections, announced a collaboration with Bharat Biotech for the co-development and commercialization of Alopexxs proprietary broad-spectrum anti-microbial vaccine, AV0328, in India and other low income and lower middle-income countries.